About Alcresta
Alcresta is a company based in Newton (United States) founded in 2011 was acquired by Linden Capital Partners in March 2024. Alcresta has raised $95.89 million across 6 funding rounds from investors including Bessemer Venture Partners, Frazier Healthcare Partners and Athyrium Capital Management. The company has 52 employees as of December 31, 2022. Alcresta offers products and services including RELiZORB and iLipase. Alcresta operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, RedHill Biopharma, Cosmo Pharmaceuticals and Seed, among others.
- Headquarter Newton, United States
- Employees 52 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alcresta Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$95.89 M (USD)
in 6 rounds
-
Latest Funding Round
$10 M (USD), Series D
Feb 28, 2020
-
Investors
Bessemer Venture Partners
& 4 more
-
Employee Count
52
as on Dec 31, 2022
-
Acquired by
Linden Capital Partners
(Mar 25, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alcresta
Alcresta offers a comprehensive portfolio of products and services, including RELiZORB and iLipase.
Breaks down fats in enteral feeding for better absorption in patients.
Patented microbead technology for fat digestion in nutritional support.
People of Alcresta
Unlock access to complete
Funding Insights of Alcresta
Alcresta has successfully raised a total of $95.89M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $10 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alcresta
Alcresta has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Bessemer Venture Partners, Frazier Healthcare Partners and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Venture capital investments and support for entrepreneurs in technology and innovation sectors.
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Alcresta
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alcresta
Investment portfolio details for Alcresta
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alcresta
Detailed financials for Alcresta
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alcresta Comparisons
Peer comparison for Alcresta
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alcresta
Alcresta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, RedHill Biopharma, Cosmo Pharmaceuticals and Seed, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal diseases are developed and provided.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
Detailed competitors of Alcresta
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alcresta
Complete news archive for Alcresta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alcresta
Alcresta was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Alcresta is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
Daniel Orlando is the current CEO of Alcresta.
Alcresta is a funded company, having raised a total of $95.89M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Alcresta is 52.
Alcresta was founded in 2011 in Newton, United States, focusing on the biotechnology sector for gastrointestinal health. A platform technology is utilized to immobilize enzymes on insoluble carriers, aiding digestion and nutrient absorption. The flagship product, Relizorb, is designed as a cartridge mimicking pancreatic lipase function. Operations center on developing and advancing these enzyme-based therapeutics for clinical applications.
Alcresta's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Alcresta offers RELiZORB and iLipase.
Alcresta has 5 investors. Key investors include Bessemer Venture Partners, Frazier Healthcare Partners, Athyrium Capital Management, Third Rock Ventures, and Linden Capital Partners.